Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.

Georges GE, Bar M, Onstad L, Yi JC, Shadman M, Flowers ME, Carpenter PA, Stewart S, Lee SJ, Holmberg LA.

Biol Blood Marrow Transplant. 2019 Oct 9. pii: S1083-8791(19)30653-6. doi: 10.1016/j.bbmt.2019.10.002. [Epub ahead of print]

PMID:
31605822
2.

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.

Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW.

Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30.

PMID:
31582314
3.

Back-to-Germline (B2G) Procedure for Antibody Devolution.

Schrade A, Bujotzek A, Spick C, Wagner M, Goerl J, Wezler X, Georges G, Kontermann RE, Brinkmann U.

Antibodies (Basel). 2019 Aug 26;8(3). pii: E45. doi: 10.3390/antib8030045.

4.

Total Body Irradiation-Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant.

Storb R, Georges GE, Gooley TA.

Biol Blood Marrow Transplant. 2019 Aug 13. pii: S1083-8791(19)30519-1. doi: 10.1016/j.bbmt.2019.08.005. [Epub ahead of print] No abstract available.

PMID:
31419567
5.

CDR-H3 loop ensemble in solution - conformational selection upon antibody binding.

Fernández-Quintero ML, Kraml J, Georges G, Liedl KR.

MAbs. 2019 Aug/Sep;11(6):1077-1088. doi: 10.1080/19420862.2019.1618676. Epub 2019 Jun 9.

6.

Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations.

Papi A, Petruzzelli S, Vezzoli S, Georges G, Fabbri LM.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900147. doi: 10.1183/13993003.00147-2019. Print 2019 Apr. No abstract available.

PMID:
31000665
7.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

8.

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation.

Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A.

Eur Respir J. 2019 May 18;53(5). pii: 1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May. No abstract available.

9.

Consider Allogeneic Bone Marrow Transplantation for Older, FitPatients with Aplastic Anemia.

Georges GE.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e69-e70. doi: 10.1016/j.bbmt.2019.01.015. Epub 2019 Jan 11. No abstract available.

PMID:
30641134
10.

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Richter H, Satz AL, Bedoucha M, Buettelmann B, Petersen AC, Harmeier A, Hermosilla R, Hochstrasser R, Burger D, Gsell B, Gasser R, Huber S, Hug MN, Kocer B, Kuhn B, Ritter M, Rudolph MG, Weibel F, Molina-David J, Kim JJ, Santos JV, Stihle M, Georges GJ, Bonfil RD, Fridman R, Uhles S, Moll S, Faul C, Fornoni A, Prunotto M.

ACS Chem Biol. 2019 Jan 18;14(1):37-49. doi: 10.1021/acschembio.8b00866. Epub 2018 Dec 16.

11.

SCALOP: sequence-based antibody canonical loop structure annotation.

Wong WK, Georges G, Ros F, Kelm S, Lewis AP, Taddese B, Leem J, Deane CM.

Bioinformatics. 2019 May 15;35(10):1774-1776. doi: 10.1093/bioinformatics/bty877.

12.

Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.

Georges GE, Doney K, Storb R.

Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Review.

13.

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, Georges GE, Nash RA, Pasquini MC, Sarantopoulos S, Storek J, Savani B, St Clair EW.

Biol Blood Marrow Transplant. 2018 Oct;24(10):1961-1964. doi: 10.1016/j.bbmt.2018.06.025. Epub 2018 Jun 25. Review.

14.

Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.

Moll S, Yasui Y, Abed A, Murata T, Shimada H, Maeda A, Fukushima N, Kanamori M, Uhles S, Badi L, Cagarelli T, Formentini I, Drawnel F, Georges G, Bergauer T, Gasser R, Bonfil RD, Fridman R, Richter H, Funk J, Moeller MJ, Chatziantoniou C, Prunotto M.

J Transl Med. 2018 Jun 1;16(1):148. doi: 10.1186/s12967-018-1524-5.

15.

Rapid Uptake of the Subcutaneous Injectable in Burkina Faso: Evidence From PMA2020 Cross-Sectional Surveys.

Georges G, Shani T, Hamadou C, Radloff S, Yoonjoung C.

Glob Health Sci Pract. 2018 Mar 30;6(1):73-81. doi: 10.9745/GHSP-D-17-00260. Print 2018 Mar 21.

16.

Antibody side chain conformations are position-dependent.

Leem J, Georges G, Shi J, Deane CM.

Proteins. 2018 Apr;86(4):383-392. doi: 10.1002/prot.25453. Epub 2018 Jan 25. Erratum in: Proteins. 2018 Aug;86(8):892.

PMID:
29318667
17.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

18.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

Green DJ, Maloney DG, Storer BE, Sandmaier BM, Holmberg LA, Becker PS, Fang M, Martin PJ, Georges GE, Bouvier ME, Storb R, Mielcarek M.

Blood Adv. 2017 Nov 9;1(24):2247-2256. doi: 10.1182/bloodadvances.2017010686. eCollection 2017 Nov 14.

19.

The Use of Ex Vivo Generated Regulatory T-Cell Preparations in a Canine Lung Allograft Model.

Abrams KV, Hwang B, Nash RA, Georges GE, Lamm W, Storer B, Madtes DK, Glenny R, Mulligan MS.

Transplantation. 2017 Oct;101(10):e326-e327. doi: 10.1097/TP.0000000000001868. No abstract available.

20.

Sphinx: merging knowledge-based and ab initio approaches to improve protein loop prediction.

Marks C, Nowak J, Klostermann S, Georges G, Dunbar J, Shi J, Kelm S, Deane CM.

Bioinformatics. 2017 May 1;33(9):1346-1353. doi: 10.1093/bioinformatics/btw823.

21.

The H3 loop of antibodies shows unique structural characteristics.

Regep C, Georges G, Shi J, Popovic B, Deane CM.

Proteins. 2017 Jul;85(7):1311-1318. doi: 10.1002/prot.25291. Epub 2017 Apr 6.

22.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

23.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

24.

Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.

Wundes A, Bowen JD, Kraft GH, Maravilla KR, McLaughlin B, von Geldern G, Georges G, Nash RA, Lu JQ.

J Neurol Sci. 2017 Feb 15;373:339-341. doi: 10.1016/j.jns.2017.01.016. Epub 2017 Jan 7.

PMID:
28131217
25.

Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum.

Georges GT, Nájera O, Sowers K, Sowers JR.

Cardiorenal Med. 2016 Nov;7(1):60-65. Epub 2016 Sep 30. Review.

26.

Hematopoietic stem cell transplantation for acquired aplastic anemia.

Georges GE, Storb R.

Curr Opin Hematol. 2016 Nov;23(6):495-500. Review.

27.

ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation.

Leem J, Dunbar J, Georges G, Shi J, Deane CM.

MAbs. 2016 Oct;8(7):1259-1268. Epub 2016 Jul 8. Erratum in: MAbs. 2018 Apr;10 (3):511-512.

28.

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.

Schmittnaegel M, Hoffmann E, Imhof-Jung S, Fischer C, Drabner G, Georges G, Klein C, Knoetgen H.

Mol Cancer Ther. 2016 Sep;15(9):2130-42. doi: 10.1158/1535-7163.MCT-16-0207. Epub 2016 Jun 28.

29.

SAbPred: a structure-based antibody prediction server.

Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C, Georges G, Kelm S, Popovic B, Deane CM.

Nucleic Acids Res. 2016 Jul 8;44(W1):W474-8. doi: 10.1093/nar/gkw361. Epub 2016 Apr 29.

30.

Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.

Cassaday RD, Alan Potts D Jr, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM.

Leuk Lymphoma. 2016 Sep;57(9):2109-18. doi: 10.3109/10428194.2016.1160080. Epub 2016 Mar 22.

31.

Length-independent structural similarities enrich the antibody CDR canonical class model.

Nowak J, Baker T, Georges G, Kelm S, Klostermann S, Shi J, Sridharan S, Deane CM.

MAbs. 2016 May-Jun;8(4):751-60. doi: 10.1080/19420862.2016.1158370.

32.

VH-VL orientation prediction for antibody humanization candidate selection: A case study.

Bujotzek A, Lipsmeier F, Harris SF, Benz J, Kuglstatter A, Georges G.

MAbs. 2016;8(2):288-305. doi: 10.1080/19420862.2015.1117720.

33.

A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.

Yun Kirby S, Zhu CQ, Kerwin EM, Stanford RH, Georges G.

COPD. 2016;13(2):167-75. doi: 10.3109/15412555.2015.1057274. Epub 2015 Oct 30.

PMID:
26516724
34.

Feasibility and tolerability of self-insertion of a transnasal tube for esophagogastroduodenoscopy: a pilot study.

Senesse P, Georges G, Séville S, Flori N, Stoebner A, Assenat E, de Forges H.

Endoscopy. 2015;47 Suppl 1 UCTN:E475-6. doi: 10.1055/s-0034-1392795. Epub 2015 Oct 19. No abstract available.

PMID:
26479292
35.

MoFvAb: Modeling the Fv region of antibodies.

Bujotzek A, Fuchs A, Qu C, Benz J, Klostermann S, Antes I, Georges G.

MAbs. 2015;7(5):838-52. doi: 10.1080/19420862.2015.1068492.

36.

A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis.

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G.

Allergy Asthma Proc. 2015 Jul-Aug;36(4):313-9. doi: 10.2500/aap.2015.36.3860.

PMID:
26108088
37.

Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.

Schmittnaegel M, Levitsky V, Hoffmann E, Georges G, Mundigl O, Klein C, Knoetgen H.

Cancer Immunol Res. 2015 Jul;3(7):764-76. doi: 10.1158/2326-6066.CIR-15-0037. Epub 2015 Feb 17.

38.

Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.

39.

Prediction of VH-VL domain orientation for antibody variable domain modeling.

Bujotzek A, Dunbar J, Lipsmeier F, Schäfer W, Antes I, Deane CM, Georges G.

Proteins. 2015 Apr;83(4):681-95. doi: 10.1002/prot.24756. Epub 2015 Feb 5.

PMID:
25641019
40.

In utero transplantation may soon be in delivery.

Georges GE.

Blood. 2014 Sep 18;124(12):1854-5. No abstract available.

PMID:
25606630
41.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

42.

TCR-MHC/peptide interaction: prospects for new anti-tumoral agents.

Weidle UH, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2014 Nov-Dec;11(6):267-77. Review.

PMID:
25422358
43.

Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice?

Khanna D, Georges GE, Couriel DR.

JAMA. 2014 Jun 25;311(24):2485-7. doi: 10.1001/jama.2014.6369. No abstract available. Erratum in: JAMA. 2014 Nov 5;312(17):1805.

44.

Effect of intranasal triamcinolone acetonide on basal hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis.

Georges G, Kim KT, Ratner P, Segall N, Qiu C.

Allergy Asthma Proc. 2014 Mar-Apr;35(2):163-70. doi: 10.2500/aap.2014.35.3728.

PMID:
24717794
45.

Proteases as activators for cytotoxic prodrugs in antitumor therapy.

Weidle UH, Tiefenthaler G, Georges G.

Cancer Genomics Proteomics. 2014 Mar-Apr;11(2):67-79. Review.

PMID:
24709544
46.

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Weidle UH, Tiefenthaler G, Schiller C, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):25-38. Review.

PMID:
24633317
47.

SAbDab: the structural antibody database.

Dunbar J, Krawczyk K, Leem J, Baker T, Fuchs A, Georges G, Shi J, Deane CM.

Nucleic Acids Res. 2014 Jan;42(Database issue):D1140-6. doi: 10.1093/nar/gkt1043. Epub 2013 Nov 8.

48.

The emerging role of new protein scaffold-based agents for treatment of cancer.

Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):155-68. Review.

PMID:
23893924
49.

Response to: monoclonal antibodies targeting CD20.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G.

MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. No abstract available.

50.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

Supplemental Content

Loading ...
Support Center